Postdocs
Silja Birte Haldrup
Exploring novel CRISPR/Cas9-based treatment strategies for OPA1-related dominant optic atrophy
Postdoc
Oxford University
Silja Birte Haldrup, Oxford University, John Radcliffe Hospital, has been awarded a postdoc research grant from the Lundbeck Foundation worth DKK 3.234.000
Dominant Optic Atrophy (DOA) is a neurodegenerative condition that primarily impacts retinal ganglion cells and the optic nerve, disrupting the transmission of visual signals from the retina to the brain. Most DOA cases are linked to pathogenic variants in the OPA1 gene. My research focuses on exploring two CRISPR/Cas9-based strategies to restore functional OPA1 levels, aiming to prevent further neurodegeneration.
